Posted on December 2, 2020 by Sitemaster
Yesterday the US Food and Drug Administration (FDA) gave its approval for the first gallium-68 prostate-specific membrane antigen imaging agent (Ga-67 PSMA-11), for the use in association with positron emission tomography (PET) scanning for the evaluation of men with suspected prostate cancer — and most particularly for those men with high-risk characteristics suggesting the possibility of metastasis, including men with newly diagnosed or recurrent disease. However, here’s the “but”… READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: gallium-68, imaging, PET, PSMA, scan | 5 Comments »
Posted on June 3, 2019 by Sitemaster
According to a presentation given yesterday at the ASCO meeting here in Chicago, PET/CT scanning with 68Ga-PSMA-11 is more accurate than 18F-fluciclovine PET/CT at detecting recurrent prostate cancer in men with early biochemical recurrence following radical prostatectomy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: fluciclovine, fluorine-18, gallium-68, PET, PET/CT, scan | 11 Comments »
Posted on April 24, 2019 by Sitemaster
A media release issued yesterday by Progenics Pharmaceuticals states that the investigational imaging agent 18F-DCFPyL changed physician behavior in the management of biochemically recurrent prostate cancer in > 65 percent of patients. … READ MORE …
Filed under: Uncategorized | Tagged: 18F-DCFPyL, biochemical, change, CT, imaging, Management, PET, recurrence, scan | Leave a comment »
Posted on January 7, 2019 by Sitemaster
A research team at the University of California, Los Angeles (UCLA) is seeking participants for a randomized, Phase III, clinical trial of the utility of 68Ga-PSMA-11 PET/CT molecular imaging for planning of salvage radiotherapy after first-line treatment for localized prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: CT, free, gallium-68, PET, PSMA-11, radiation, salvage, scan, SRT, therapy | 4 Comments »
Posted on October 17, 2018 by Sitemaster
The “game changer” statement above comes from an independent review of the potential value of gallium-86-labeled prostate-specific molecular antigen (68Ga PSMA) PET scanning in the evaluation of selected men with prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: Diagnosis, gallium-68, PET, prognosis, PSMA, scan, work-up | 4 Comments »
Posted on October 5, 2018 by Sitemaster
In a media release issued earlier this morning, Progenics Pharmaceuticals has announced the outcome of a Phase II/III trial of their proprietary, PSMA-targeted imaging agent PyL (also known as 18F-DCFPyL) for identification of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: 18F-DCFPyL, imaging, PET, PSMA, PyL | 8 Comments »
Posted on September 12, 2018 by Sitemaster
A newly-reported set of data from an Australian clinical research team has now shown that 68Ga PSMA PET/CT scans changed the staging and the management of men after initial diagnosis and prior to first-line treatment compared to traditional CT and bone scanning. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: CT, gallium-68, PET, PSMA, risk, scan | 1 Comment »
Posted on September 4, 2018 by Sitemaster
A randomized clinical trial of the 68Ga-PSMA-11 PET indicator for men with a recurrence after radical prostatectomy has just been initiated at the University of California Los Angeles (UCLA). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: gallium-68, PET, radiation, salvage, scan, trial | 1 Comment »
Posted on February 26, 2018 by Sitemaster
The new PSMA-based PET scans provide a way to locate exactly where the cancer has spread to after an unsuccessful prostatectomy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: change, gallium-68, PET, plan, PSMA, radiation, salvage, scan, Treatment | 6 Comments »
Posted on October 18, 2017 by Sitemaster
The re-treatment of patients with recurrent prostate cancer after initial, first-line treatment for what was initially diagnosed as localized disease can be complicated. Success (i.e., effective re-treatment with curative intent) in the re-treatment of such patients is often dependent on the ability to identify exactly where recurrence has occurred. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: gallium-68, PET, PSMA, radio-guided, recurrent, scan, surgery | 3 Comments »
Posted on September 28, 2017 by Sitemaster
The value of many cancer-related tests is actually based on whether the results of the particular test change the way that physicians plan to treat specific patients (hopefully for the better). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Axumin, fluciclovine, PET, recurrence, scan, Treatment | Leave a comment »
Posted on December 21, 2016 by Sitemaster
Because the new imaging agent known as [18F]fluciclovine (Axumin®) is the only such imaging agent approved for use in the US — other than the [11C]choline imaging agent (use of which is limited to the Mayo Clinic) — we have been monitoring access to this new agent with some interest. … READ MORE …
Filed under: Living with Prostate Cancer, Uncategorized | Tagged: Axumin, imaging, PET, scan, [18F]fluciclovine | 4 Comments »
Posted on October 12, 2016 by Sitemaster
As many readers will be aware, there has been a lot of ongoing research using the gallium-68 (68Ga) radioisotope linked to various forms of prostate-specific membrane antigen (PSMA) in concert with PET scan imaging to identify sites of early recurrence of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: copper-64, gallium-68, PET, PSMA, radioligand, scan | 7 Comments »
Posted on September 8, 2016 by Sitemaster
Back in May this year we reported that the US Food and Drug Administration had approved a new type of imaging agent known as [18F]fluciclovine (Axumin®) for use in association with PET scans in men with recurrent prostate cancer that might have spread to other parts of the body, but which was not evident on older forms of scan. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: Axumin, fluciclovine, PET, scan | Leave a comment »
Posted on February 26, 2016 by Sitemaster
A new review article suggests the possibility that radiolabeled prostate specific membrane antigens (PSMAs) and PET scans may, at some point in the not too distant future, replace bone and CT scans in diagnosis and monitoring of men with advanced forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management | Tagged: bone, CT, gallium-68, PET, PSMA, scan | 4 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 